Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Warns Of Cost-Shifting With Use Of Radiology Benefit Managers

This article was originally published in The Gray Sheet

Executive Summary

As policymakers consider the cost-saving prospects of requiring imaging scans to be pre-authorized by radiology benefit managers for Medicare coverage, industry is arguing that the policy may simply shift costs to providers.

You may also be interested in...



MedPAC Forwards More Ideas To Reduce Advanced Imaging Spending

The Medicare Payment Advisory Commission outlined four draft recommendations last week intended to either reduce payments for or control use of advanced imaging tools. Among the ideas: a prior authorization program specifically targeting physicians who order the most imaging scans.

Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.

Aduhelm’s Post-Marketing Studies: At Least One More Data Dump Likely Required By NIH

Pulling the controversial Alzheimer’s drug’s BLA should not exempt Biogen from fulfilling ClinicalTrials.gov reporting requirements for two key studies, even if the research gets terminated, former head of the NIH data repository tells the Pink Sheet.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel